# A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

> **NCT05066230** · PHASE3 · TERMINATED · sponsor: **Kodiak Sciences Inc** · enrollment: 253 (actual)

## Conditions studied

- Non-proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** KSI-301
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT05066230
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-07
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-31
- **Target enrollment:** 253 (ACTUAL)
- **Why stopped:** All patients completed the primary endpoint assessments. Additional follow-up after the primary endpoint was deemed not necessary by the Sponsor.
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066230, "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05066230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*